InstalabLoading...
InstalabLoading...
Candida albicans is a yeast that lives in nearly everyone's gut, mouth, and skin. Your immune system keeps it in check, and one of the ways it does this is by producing IgA (immunoglobulin A) antibodies, a class of immune proteins that patrol your mucosal surfaces. When this yeast shifts from a harmless passenger to an active irritant or infection, IgA production changes. This test measures the IgA antibodies in your blood that are specifically directed against Candida albicans.
The challenge with this test is that almost all healthy adults have some level of Candida albicans IgA antibodies, simply from daily exposure to a yeast that already lives in their body. That means a single result cannot tell you whether you have a problem. What matters is the level in context: how high it is, whether it is changing over time, and what your symptoms and other test results look like. This is an exploratory marker, not one with standardized clinical cutpoints, and interpreting it requires more nuance than a simple "normal" or "abnormal" label.
Candida albicans Ab IgA (Candida albicans antibody, immunoglobulin A) measures one specific class of antibody your immune system makes against this yeast. IgA is the dominant antibody at mucosal surfaces, the wet linings of your gut, mouth, and respiratory tract. The IgA that shows up in your blood (serum IgA) is produced by specialized immune cells called plasma cells, mostly in your bone marrow and lymph tissue, and it reflects your body's overall mucosal exposure and response to Candida.
This is different from salivary IgA, which is produced locally in your mouth and reflects oral immune activity specifically. The blood test captures a broader picture. In a study using a specialized lab technique to measure antibody concentrations, about half of healthy blood donors had very low or undetectable Candida IgA (below 5 µg/mL), while IgG antibodies against Candida were detectable in all of them. Hospitalized adults showed a wider range of IgA levels, but this could not be tied to any single factor like age, sex, or confirmed infection.
The central difficulty with Candida antibody testing is that your body makes these antibodies whether Candida is behaving itself or not. In healthy adults and hospitalized patients alike, there is a large overlap in antibody levels between people who are simply carrying the yeast and people who have genuine infection. No single antibody level can reliably diagnose Candida infection on its own.
This is why serial measurements, checking the trend over time rather than relying on a one-time reading, are far more informative. A rising antibody concentration suggests increasing immune activation against Candida, which could mean the yeast is becoming more active. A stable or low reading in the presence of symptoms is also meaningful. The number only tells a story when you watch it move.
Elevated serum IgA antibodies to Candida and related yeast sugars (including a marker called ASCA, or anti-Saccharomyces cerevisiae antibodies) have been found at higher levels in people with Crohn's disease, a chronic inflammatory bowel condition. In a study of patients with orofacial granulomatosis (a condition causing swelling in the mouth and face) and Crohn's disease, raised serum IgA antibodies to both Candida albicans and Saccharomyces cerevisiae correlated with gut inflammation.
A separate line of research has linked Candida albicans antibodies to celiac disease. In a study of 226 people, antibodies that react with a Candida surface protein called Hwp1 (hyphal wall protein 1) cross-reacted with gliadin, one of the gluten proteins that triggers celiac disease. This suggests that in genetically susceptible people, Candida infection could potentially contribute to the onset of celiac disease through a case of mistaken identity by the immune system.
People with alcohol-related liver disease show lower fungal diversity in the gut and an overgrowth of Candida species. In this population, higher serum levels of ASCA (a related yeast antibody marker, not Candida albicans IgA specifically) were associated with worse 90-day survival. Both markers reflect the body's immune response to yeast overgrowth in the gut, and the pattern suggests that heavy yeast-driven immune activation in the setting of liver disease is a bad sign.
In some contexts, lower Candida-reactive IgA is associated with worse outcomes, not better ones. In a study of 122 HIV patients who had not yet started antiretroviral therapy, those with lower salivary (not blood) Candida-reactive IgA had higher oral yeast counts and more clinical oral candidiasis (thrush). This suggests that mucosal IgA may actually protect against yeast overgrowth, and that a weak IgA response leaves the door open for Candida to flourish.
This creates an important interpretive nuance: very high levels may signal that your immune system is working overtime against an active yeast challenge, while very low levels may mean your mucosal defenses are not keeping Candida in check. Neither extreme is reassuring on its own.
There are no widely standardized clinical cutpoints for Candida albicans IgA antibodies. The ranges that exist come from individual research labs and vary depending on the assay method used. The most detailed published data comes from a study in healthy blood donors and hospitalized adults, which measured antibodies in micrograms per milliliter (µg/mL, a measure of concentration). These values are illustrative orientation from a single assay platform, not universal targets. Your lab will report results using its own method and units.
| Finding | Level | What It Suggests |
|---|---|---|
| Most healthy blood donors | Below 5 µg/mL (very low or undetectable IgA) | Normal background exposure with minimal IgA response |
| Some healthy and hospitalized adults | 5 to 45 µg/mL | Detectable IgA; common without clinical infection |
| Occasional hospitalized adults | Above 45 µg/mL | Higher immune activation; may reflect colonization, infection, or mucosal inflammation |
Because assays differ significantly, always compare your results within the same lab over time. A result of "20" from one lab cannot be compared to "20" from another lab using a different method. The trend within the same assay is what matters.
The biggest source of misleading results is the inherent overlap between healthy colonization and disease. A positive or elevated result does not mean you have invasive candidiasis or even that Candida is causing your symptoms. In ICU studies, Candida antibody tests (including the related germ tube antibody test) often came back positive in patients who turned out to have colonization, not infection. Guidelines for fungal diagnostics stress that antibody results must be interpreted alongside clinical risk factors, cultures, and other biomarkers rather than in isolation.
A single Candida albicans IgA reading tells you almost nothing in isolation. The value of this test comes from watching the number move. If you are testing because of chronic gut symptoms, recurrent yeast infections, or a suspicion of fungal overgrowth, get a baseline, then retest in 3 to 6 months. If you are making dietary or probiotic changes aimed at reducing yeast burden, a follow-up test can show whether your immune response is shifting.
Because this is an exploratory marker without established clinical thresholds, your own trajectory is more meaningful than any single cutpoint. A level that is dropping over time after an intervention is a different story than a level that is climbing. Track results from the same lab using the same assay to make comparisons valid.
If your Candida albicans IgA comes back elevated, the first step is context. Are you having symptoms like chronic bloating, oral thrush, recurrent vaginal yeast infections, or unexplained skin issues? Do you have risk factors like recent antibiotic use, immunosuppression, or heavy alcohol intake? An elevated result with no symptoms and no risk factors is far less concerning than one accompanied by a clear clinical picture.
For a meaningful workup, consider pairing this test with Candida albicans IgG and IgM antibodies (to see the full antibody profile), a stool analysis that includes Candida culture, and markers of gut inflammation like calprotectin. If your result is very high and you have relevant symptoms, a conversation with a gastroenterologist or infectious disease specialist can help determine whether further investigation, such as endoscopy or antifungal treatment, is warranted. Do not treat a single elevated antibody level as proof of "systemic candida" without corroborating evidence.
Evidence-backed interventions that affect your Candida IgA level
Candida Albicans Ab IgA is best interpreted alongside these tests.